Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi Builds Women's Health And Sexual Health Portfolio With QuatRx Deal

This article was originally published in PharmAsia News

Executive Summary

The U.S. subsidiary of Shionogi acquired global development and marketing rights to QuatRx Pharmaceuticals' selective estrogen receptor modulator ospemifene, building on the company's sexual medicine and women's health portfolio
Advertisement

Related Content

Shionogi’s Osphena May Offer Safer Alternative To Estrogen
Deals Of The Week: GSK/Abbott, AZ/Merck, Bausch & Lomb/NicOX...
Deals Of The Week: GSK/Abbott, AZ/Merck, Bausch & Lomb/NicOX...
Shionogi To Divest Contract Manufacturer To Focus On Prescription Business
Shionogi To Divest Contract Manufacturer To Focus On Prescription Business
Shionogi To Divest Contract Manufacturer To Focus On Prescription Business
Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say
Shionogi Gains U.S. Sales Force With $1.4 Billion Sciele Acquisition
QuatRx Anticipates NDA Filing For Vaginal Atrophy Therapy Ophena In 2009/2010
QuatRx Anticipates NDA Filing For Vaginal Atrophy Therapy Ophena In 2009/2010
Advertisement
UsernamePublicRestriction

Register

SC074420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel